<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02419118</url>
  </required_header>
  <id_info>
    <org_study_id>181114</org_study_id>
    <nct_id>NCT02419118</nct_id>
  </id_info>
  <brief_title>&quot;Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab &quot;</brief_title>
  <acronym>DARA</acronym>
  <official_title>&quot;Monoclonal Antibodies for Treatment of Multiple Myeloma. Present Status and Aspects of Effector Mechanisms With Emphasis on the CD38 Antibody Daratumumab &quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vejle Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vejle Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Daratumumab is a new treatment for patients with myeloma. While many patients benefit from
      this treatment some do not and the mechanism(s) of failure are poorly understood. This study
      aims to clarify aspects of resistance to treatment with daratumumab in order to improve
      patient outcomes in the future.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The effector mechanisms of daratumumab have been extensively studied in vitro, but the in
      vivo correlates and key determinants of success or failure when daratumumab is used alone or
      in combination with lenalidomide for treatment of patients with myeloma have not been
      clarified.

      There is potentially a wide spectrum of factors that may influence the quality and duration
      of response following treatment with daratumumab. The integrity of the patient's immune
      system may be important. Prior lines of chemotherapy or the myeloma disease itself may impair
      humural (i.e. complement) or cellular (i.e. ADCC) effector mechanisms that are of importance
      for the response to daratumumab. Also intrinsic properties of the tumor cells or interactions
      between myeloma cells and the bone marrow microenvironment could make the myeloma cells
      refractory to daratumumab.

      A better understanding of these variables may enable us to improve the quality and duration
      of daratumumab-induced responses and make daratumumab-based therapies more effective in the
      near future.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Actual">October 1, 2015</completion_date>
  <primary_completion_date type="Actual">October 1, 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response by IMWG criteria</measure>
    <time_frame>4 weeks</time_frame>
    <description>Assessed by M-component in blood and urine samples</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>T cell subset numbers</measure>
    <time_frame>4 weeks</time_frame>
    <description>Measured in bood and bone marrow aspirates</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Dara len dex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daratumumab in combination with lenalidomide and dexamethasone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Len dex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lenalidomide in combination with dexamethasone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daratumumab</intervention_name>
    <description>Treatment of myeloma patients with Daratumumab</description>
    <arm_group_label>Dara len dex</arm_group_label>
    <other_name>CD38 monoclonal antibody</other_name>
    <other_name>HuMax CD38</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Treatment of myeloma patients</description>
    <arm_group_label>Dara len dex</arm_group_label>
    <arm_group_label>Len dex</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Treatment of myeloma patients</description>
    <arm_group_label>Dara len dex</arm_group_label>
    <arm_group_label>Len dex</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Accepted for a clinical trial with Daratumumab for myeloma

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Torben Plesner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vejle Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Hematology Vejle Hospital</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <results_reference>
    <citation>Franssen LE, van de Donk NW, Emmelot ME, Roeven MW, Schaap N, Dolstra H, Hobo W, Lokhorst HM, Mutis T. The impact of circulating suppressor cells in multiple myeloma patients on clinical outcome of DLIs. Bone Marrow Transplant. 2015 Jun;50(6):822-8. doi: 10.1038/bmt.2015.48. Epub 2015 Mar 23.</citation>
    <PMID>25798669</PMID>
  </results_reference>
  <results_reference>
    <citation>Overdijk MB, Verploegen S, BÃ¶gels M, van Egmond M, Lammerts van Bueren JJ, Mutis T, Groen RW, Breij E, Martens AC, Bleeker WK, Parren PW. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs. 2015;7(2):311-21. doi: 10.1080/19420862.2015.1007813.</citation>
    <PMID>25760767</PMID>
  </results_reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2015</study_first_submitted>
  <study_first_submitted_qc>April 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2015</study_first_posted>
  <last_update_submitted>November 6, 2017</last_update_submitted>
  <last_update_submitted_qc>November 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myeloma</keyword>
  <keyword>monoclonal antibody</keyword>
  <keyword>Daratumumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Daratumumab</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

